In the Clinic
Results from a phase 2 clinical trial report a combination of two checkpoint inhibitor immunotherapy drugs given before melanoma surgery prevents this aggressive skin cancer from coming back. This new drug combination also has fewer side effects than other immunotherapy treatments.